Janssen Search
Search results
Commercialization of Our Medicines
Commercialization: Ensuring the Reach of Our Medicines to Patient Populations on a Global Scale “I’m deeply inspired by the legacy of this team, which for more than two decades has been a world leader in the development of transformational medicines, ...
Oncology Discovery & Early Development
Discovery and Early Development “We focus our deep expertise and understanding of disease biology and scientific innovation on specific tumor types with the greatest need for new treatment options.” Jeff Infante, M.D. Vice President, Oncology Early ...
Debi Watson
DEBI WATSON VICE PRESIDENT BUSINESS DEVELOPMENT, ONCOLOGY Debi Watson is the head of the Oncology Business Development Group at Johnson & Johnson Innovation, Janssen Business Development. In this role, she leads Business Development Strategy in ...
Tumor Immunoenvironment
Apr 02, 2015 Evolving Tumor Microenvironment Strategy Our evolving strategy centers on innovative approaches to drug development based on a deep understanding of the critical relationships between cancer cells and the tumor microenvironment, * with ...
Dave Yazujian, M.S.
As the Strategy and Operations Support Leader for the Disease Interception Accelerator (DIA), Dave Yazujian drives the development and execution of the DIA strategy, ensuring operational efficiency and effectiveness and integrating input from Janssen ...
Richard Tillyer, Ph.D.
RICHARD TILLYER, Ph.D. Global Head Discovery and Manufacturing Sciences Richard Tillyer, Ph.D, is Global Head, Discovery and Manufacturing Sciences, Johnson & Johnson Innovative Medicine. In this role, he leads an integrated discovery and ...
Terence Rooney, M.D.
TERENCE ROONEY, M.D. VICE PRESIDENT RHEUMATOLOGY IMMUNOLOGY DISEASE AREA LEADER Terence Rooney, M.D., is Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this ...
Silvia S. Chen, Ph.D.
SILVIA S. CHEN, PH.D. HEAD OF CHINA LUNG CANCER INITIATIVE AT JOHNSON & JOHNSON AND WORLD WITHOUT DISEASE ACCELERATOR As Head of China for the Lung Cancer Initiative (LCI) at Johnson & Johnson (J&J) and the World Without Disease Accelerator ...
Tina Soares
TINA SOARES GLOBAL HEAD SCIENTIFIC & CLINICAL OPERATIONS THE LUNG CANCER INITIATIVE AT J&J AND WORLD WITHOUT DISEASE ACCELERATOR As Global Head, Scientific & Clinical Operations for the Lung Cancer Initiative (LCI) at Johnson & Johnson (J ...
Celebrating a New Era in Bladder Cancer Treatment
Celebrating a New Era in Bladder Cancer Treatment As we seek to increase awareness of bladder cancer and the patients we serve, it is important to celebrate the enormous strides we have made in further understanding this disease. Recent scientific ...